BRAFTOVI (encorafenib) capsules

BRAFTOVI can be used in combination with binimetinib (called MEKTOVI) to treat adult patients who have a type of skin cancer called melanoma, which has spread to other parts of the body, or cannot be removed by surgery, and which has a particular change (mutation) in the gene that produces a protein called BRAF.

BRAFTOVI (encorafenib) capsules Price In India Ahmedabad Bengaluru Chennai Kolkata Mumbai
BRAFTOVI (encorafenib) capsules

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

BRAFTOVI (encorafenib) capsules

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery.

BRAFTOVI is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Encorafenib, is a medication for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. In June 2018, it was approved by the FDA in combination with binimetinib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, the US Food and Drug Administration approved encorafenib with binimetinib for adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Drug (Brand / Generic): BRAFTOVI / encorafenib
Current Indication: treat melanoma
Approval Date: Aug 1, 2019

Array BioPharma
Capsules: 50 mg and 75 mg.

BRAFTOVI (encorafenib) is supplied as 50 mg and 75 mg hard gelatin capsules. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see
USP Controlled Room Temperature]. Do not use if safety seal under cap is broken or missing. Dispense in
original bottle. Do not remove desiccant. Protect from moisture. Keep container tightly closed.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.